PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of envhperEnvironmental Health PerspectivesBrowse ArticlesAbout EHPGeneral InformationAuthorsMediaProgramsPartnerships
 
Environ Health Perspect. 1997 June; 105(Suppl 4): 699–737.
PMCID: PMC1470055
Research Article

12th meeting of the Scientific Group on Methodologies for the Safety Evaluation of Chemicals: susceptibility to environmental hazards.

Abstract

The 12th meeting of the Scientific Group on Methodologies for the Safety Evaluation of Chemicals (SGOMSEC) considered the topic of methodologies for determining human and ecosystem susceptibility to environmental hazards. The report prepared at the meeting describes measurement of susceptibility through the use of biological markers of exposure, biological markers of effect, and biomarkers directly indicative of susceptibility of humans or of ecosystems. The utility and validity of these biological markers for the study of susceptibility are evaluated, as are opportunities for developing newer approaches for the study of humans or of ecosystems. For the first time a SGOMSEC workshop also formally considered the issue of ethics in relation to methodology, an issue of particular concern for studies of susceptibility.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (9.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Nebert DW, Nelson DR. P450 gene nomenclature based on evolution. Methods Enzymol. 1991;206:3–11. [PubMed]
  • Lauwerys RR, Buchet JP, Roels H. The relationship between cadmium exposure or body burden and the concentration of cadmium in blood and urine in man. Int Arch Occup Environ Health. 1976 Mar 9;36(4):275–285. [PubMed]
  • van Schooten FJ, Hillebrand MJ, van Leeuwen FE, van Zandwijk N, Jansen HM, den Engelse L, Kriek E. Polycyclic aromatic hydrocarbon--DNA adducts in white blood cells from lung cancer patients: no correlation with adduct levels in lung. Carcinogenesis. 1992 Jun;13(6):987–993. [PubMed]
  • Hemminki K. DNA adducts and mutations in occupational and environmental biomonitoring. Environ Health Perspect. 1997 Jun;105 (Suppl 4):823–827. [PMC free article] [PubMed]
  • Costa M, Zhitkovich A, Toniolo P. DNA-protein cross-links in welders: molecular implications. Cancer Res. 1993 Feb 1;53(3):460–463. [PubMed]
  • Soskolne CL. Ethical, social, and legal issues surrounding studies of susceptible populations and individuals. Environ Health Perspect. 1997 Jun;105 (Suppl 4):837–841. [PMC free article] [PubMed]
  • Kosnett MJ, Becker CE, Osterloh JD, Kelly TJ, Pasta DJ. Factors influencing bone lead concentration in a suburban community assessed by noninvasive K x-ray fluorescence. JAMA. 1994 Jan 19;271(3):197–203. [PubMed]
  • Romieu I, Carreon T, Lopez L, Palazuelos E, Rios C, Manuel Y, Hernandez-Avila M. Environmental urban lead exposure and blood lead levels in children of Mexico City. Environ Health Perspect. 1995 Nov;103(11):1036–1040. [PMC free article] [PubMed]
  • Lindstedt G, Gottberg I, Holmgren B, Jonsson T, Karlsson G. Individual mercury exposure of chloralkali workers and its relation to blood and urinary mercury levels. Scand J Work Environ Health. 1979 Mar;5(1):59–69. [PubMed]
  • Giovanoli-Jakubczak T, Greenwood MR, Smith JC, Clarkson TW. Determination of total and inorganic mercury in hair by flameless atomic absorption, and of methylmercury by gas chromatography. Clin Chem. 1974 Feb;20(2):222–229. [PubMed]
  • Bernard A, Lauwerys R. Cadmium, NAG activity, and beta 2-microglobulin in the urine of cadmium pigment workers. Br J Ind Med. 1989 Sep;46(9):679–680. [PMC free article] [PubMed]
  • McLellan JS, Thomas BJ, Fremlin JH, Harvey TC. Cadmium-its in vivo detection in man. Phys Med Biol. 1975 Jan;20(1):88–95. [PubMed]
  • Anwar WA. Biomarkers of human exposure to pesticides. Environ Health Perspect. 1997 Jun;105 (Suppl 4):801–806. [PMC free article] [PubMed]
  • Coye MJ, Lowe JA, Maddy KJ. Biological monitoring of agricultural workers exposed to pesticides: II. Monitoring of intact pesticides and their metabolites. J Occup Med. 1986 Aug;28(8):628–636. [PubMed]
  • Wolfe HR, Durham WF, Armstrong JF. Urinary excretion of insecticide metabolites. Excretion of para-nitrophenol and DDA as indicators of exposure to parathion. Arch Environ Health. 1970 Dec;21(6):711–716. [PubMed]
  • Comer SW, Staiff DC, Armstrong JF, Wolfe HR. Exposure of workers to carbaryl. Bull Environ Contam Toxicol. 1975 Apr;13(4):385–391. [PubMed]
  • Walker CH. Biochemical responses as indicators of toxic effects of chemicals in ecosystems. Toxicol Lett. 1992 Dec;64-65 Spec No:527–533. [PubMed]
  • Ciesielski S, Loomis DP, Mims SR, Auer A. Pesticide exposures, cholinesterase depression, and symptoms among North Carolina migrant farmworkers. Am J Public Health. 1994 Mar;84(3):446–451. [PubMed]
  • Elovaara E, Heikkilä P, Pyy L, Mutanen P, Riihimäki V. Significance of dermal and respiratory uptake in creosote workers: exposure to polycyclic aromatic hydrocarbons and urinary excretion of 1-hydroxypyrene. Occup Environ Med. 1995 Mar;52(3):196–203. [PMC free article] [PubMed]
  • Ovrebø S, Fjeldstad PE, Grzybowska E, Kure EH, Chorazy M, Haugen A. Biological monitoring of polycyclic aromatic hydrocarbon exposure in a highly polluted area of Poland. Environ Health Perspect. 1995 Sep;103(9):838–843. [PMC free article] [PubMed]
  • Lucas JN, Tenjin T, Straume T, Pinkel D, Moore D, 2nd, Litt M, Gray JW. Rapid human chromosome aberration analysis using fluorescence in situ hybridization. Int J Radiat Biol. 1989 Jul;56(1):35–44. [PubMed]
  • Rosin MP. The use of the micronucleus test on exfoliated cells to identify anti-clastogenic action in humans: a biological marker for the efficacy of chemopreventive agents. Mutat Res. 1992 Jun;267(2):265–276. [PubMed]
  • Anwar WA, Rosin MP. Reduction in chromosomal damage in schistosomiasis patients after treatment with praziquantel. Mutat Res. 1993 Jan;298(3):179–185. [PubMed]
  • Lähdetie J. Occupation- and exposure-related studies on human sperm. J Occup Environ Med. 1995 Aug;37(8):922–930. [PubMed]
  • Hagmar L, Brøgger A, Hansteen IL, Heim S, Högstedt B, Knudsen L, Lambert B, Linnainmaa K, Mitelman F, Nordenson I, et al. Cancer risk in humans predicted by increased levels of chromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. Cancer Res. 1994 Jun 1;54(11):2919–2922. [PubMed]
  • Bonassi S, Abbondandolo A, Camurri L, Dal Prá L, De Ferrari M, Degrassi F, Forni A, Lamberti L, Lando C, Padovani P, et al. Are chromosome aberrations in circulating lymphocytes predictive of future cancer onset in humans? Preliminary results of an Italian cohort study. Cancer Genet Cytogenet. 1995 Feb;79(2):133–135. [PubMed]
  • Norppa H. Cytogenetic markers of susceptibility: influence of polymorphic carcinogen-metabolizing enzymes. Environ Health Perspect. 1997 Jun;105 (Suppl 4):829–835. [PMC free article] [PubMed]
  • Wiencke JK, Pemble S, Ketterer B, Kelsey KT. Gene deletion of glutathione S-transferase theta: correlation with induced genetic damage and potential role in endogenous mutagenesis. Cancer Epidemiol Biomarkers Prev. 1995 Apr-May;4(3):253–259. [PubMed]
  • Lucas JN, Tenjin T, Straume T, Pinkel D, Moore D, 2nd, Litt M, Gray JW. Rapid human chromosome aberration analysis using fluorescence in situ hybridization. Int J Radiat Biol. 1989 Jul;56(1):35–44. [PubMed]
  • Rupa DS, Hasegawa L, Eastmond DA. Detection of chromosomal breakage in the 1cen-1q12 region of interphase human lymphocytes using multicolor fluorescence in situ hybridization with tandem DNA probes. Cancer Res. 1995 Feb 1;55(3):640–645. [PubMed]
  • Lipkowitz S, Garry VF, Kirsch IR. Interlocus V-J recombination measures genomic instability in agriculture workers at risk for lymphoid malignancies. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5301–5305. [PubMed]
  • Bell DA, Liu Y, Cortopassi GA. Occurrence of bcl-2 oncogene translocation with increased frequency in the peripheral blood of heavy smokers. J Natl Cancer Inst. 1995 Feb 1;87(3):223–224. [PubMed]
  • Wiencke JK, Wrensch MR, Miike R, Petrakis NL. Individual susceptibility to induced chromosome damage and its implications for detecting genotoxic exposures in human populations. Cancer Res. 1991 Oct 1;51(19):5266–5269. [PubMed]
  • Cervenka J, Hirsch BA. Cytogenetic differentiation of Fanconi anemia, "idiopathic" aplastic anemia, and Fanconi anemia heterozygotes. Am J Med Genet. 1983 Jun;15(2):211–223. [PubMed]
  • Wiencke JK, Christiani DC, Kelsey KT. Bimodal distribution of sensitivity to SCE induction by diepoxybutane in human lymphocytes. I. Correlation with chromosomal aberrations. Mutat Res. 1991 May;248(1):17–26. [PubMed]
  • Sorsa M, Osterman-Golkar S, Peltonen K, Saarikoski ST, Sram R. Assessment of exposure to butadiene in the process industry. Toxicology. 1996 Oct 28;113(1-3):77–83. [PubMed]
  • Norppa H, Hirvonen A, Järventaus H, Uusküla M, Tasa G, Ojajärvi A, Sorsa M. Role of GSTT1 and GSTM1 genotypes in determining individual sensitivity to sister chromatid exchange induction by diepoxybutane in cultured human lymphocytes. Carcinogenesis. 1995 Jun;16(6):1261–1264. [PubMed]
  • Tucker JD, Auletta A, Cimino MC, Dearfield KL, Jacobson-Kram D, Tice RR, Carrano AV. Sister-chromatid exchange: second report of the Gene-Tox Program. Mutat Res. 1993 Sep;297(2):101–180. [PubMed]
  • Oikawa A, Sakai S, Horaguchi K, Tohda H. Sensitivities of peripheral lymphocytes from healthy humans to induction of sister chromatid exchanges by chemicals. Cancer Res. 1983 Jan;43(1):439–442. [PubMed]
  • Kelsey KT, Christiani DC, Wiencke JK. Bimodal distribution of sensitivity to SCE induction by diepoxybutane in human lymphocytes. II. Relationship to baseline SCE frequency. Mutat Res. 1991 May;248(1):27–33. [PubMed]
  • Hallier E, Langhof T, Dannappel D, Leutbecher M, Schröder K, Goergens HW, Müller A, Bolt HM. Polymorphism of glutathione conjugation of methyl bromide, ethylene oxide and dichloromethane in human blood: influence on the induction of sister chromatid exchanges (SCE) in lymphocytes. Arch Toxicol. 1993;67(3):173–178. [PubMed]
  • Kelsey KT, Wiencke JK, Ward J, Bechtold W, Fajen J. Sister-chromatid exchanges, glutathione S-transferase theta deletion and cytogenetic sensitivity to diepoxybutane in lymphocytes from butadiene monomer production workers. Mutat Res. 1995 Dec;335(3):267–273. [PubMed]
  • Uusküla M, Järventaus H, Hirvonen A, Sorsa M, Norppa H. Influence of GSTM1 genotype on sister chromatid exchange induction by styrene-7,8-oxide and 1,2-epoxy-3-butene in cultured human lymphocytes. Carcinogenesis. 1995 Apr;16(4):947–950. [PubMed]
  • Landi S, Ponzanelli I, Hirvonen A, Norppa H, Barale R. Repeated analysis of sister chromatid exchange induction by diepoxybutane in cultured human lymphocytes: effect of glutathione S-transferase T1 and M1 genotype. Mutat Res. 1996 Mar 26;351(1):79–85. [PubMed]
  • Pelin K, Hirvonen A, Norppa H. Influence of erythrocyte glutathione S-transferase T1 on sister chromatid exchanges induced by diepoxybutane in cultured human lymphocytes. Mutagenesis. 1996 Mar;11(2):213–215. [PubMed]
  • Cheng TJ, Christiani DC, Xu X, Wain JC, Wiencke JK, Kelsey KT. Glutathione S-transferase mu genotype, diet, and smoking as determinants of sister chromatid exchange frequency in lymphocytes. Cancer Epidemiol Biomarkers Prev. 1995 Jul-Aug;4(5):535–542. [PubMed]
  • van Poppel G, de Vogel N, van Balderen PJ, Kok FJ. Increased cytogenetic damage in smokers deficient in glutathione S-transferase isozyme mu. Carcinogenesis. 1992 Feb;13(2):303–305. [PubMed]
  • Heddle JA, Cimino MC, Hayashi M, Romagna F, Shelby MD, Tucker JD, Vanparys P, MacGregor JT. Micronuclei as an index of cytogenetic damage: past, present, and future. Environ Mol Mutagen. 1991;18(4):277–291. [PubMed]
  • Fenech M, Morley AA. Measurement of micronuclei in lymphocytes. Mutat Res. 1985 Feb-Apr;147(1-2):29–36. [PubMed]
  • Norppa H, Renzi L, Lindholm C. Detection of whole chromosomes in micronuclei of cytokinesis-blocked human lymphocytes by antikinetochore staining and in situ hybridization. Mutagenesis. 1993 Nov;8(6):519–525. [PubMed]
  • Norppa H, Luomahaara S, Heikanen H, Roth S, Sorsa M, Renzi L, Lindholm C. Micronucleus assay in lymphocytes as a tool to biomonitor human exposure to aneuploidogens and clastogens. Environ Health Perspect. 1993 Oct;101 (Suppl 3):139–143. [PMC free article] [PubMed]
  • Richard F, Muleris M, Dutrillaux B. The frequency of micronuclei with X chromosome increases with age in human females. Mutat Res. 1994 Feb;316(1):1–7. [PubMed]
  • Catalán J, Autio K, Wessman M, Lindholm C, Knuutila S, Sorsa M, Norppa H. Age-associated micronuclei containing centromeres and the X chromosome in lymphocytes of women. Cytogenet Cell Genet. 1995;68(1-2):11–16. [PubMed]
  • Nath J, Tucker JD, Hando JC. Y chromosome aneuploidy, micronuclei, kinetochores and aging in men. Chromosoma. 1995 Jul;103(10):725–731. [PubMed]
  • Ballarin C, Sarto F, Giacomelli L, Bartolucci GB, Clonfero E. Micronucleated cells in nasal mucosa of formaldehyde-exposed workers. Mutat Res. 1992 Jul;280(1):1–7. [PubMed]
  • McGinniss MJ, Nicklas JA, Albertini RJ. Molecular analyses of in vivo hprt mutations in human T-lymphocytes: IV. Studies in newborns. Environ Mol Mutagen. 1989;14(4):229–237. [PubMed]
  • Cole J, Skopek TR. International Commission for Protection Against Environmental Mutagens and Carcinogens. Working paper no. 3. Somatic mutant frequency, mutation rates and mutational spectra in the human population in vivo. Mutat Res. 1994 Jan;304(1):33–105. [PubMed]
  • Perera FP, Dickey C, Santella R, O'Neill JP, Albertini RJ, Ottman R, Tsai WY, Mooney LA, Savela K, Hemminki K. Carcinogen-DNA adducts and gene mutation in foundry workers with low-level exposure to polycyclic aromatic hydrocarbons. Carcinogenesis. 1994 Dec;15(12):2905–2910. [PubMed]
  • Perera FP, Tang DL, O'Neill JP, Bigbee WL, Albertini RJ, Santella R, Ottman R, Tsai WY, Dickey C, Mooney LA, et al. HPRT and glycophorin A mutations in foundry workers: relationship to PAH exposure and to PAH-DNA adducts. Carcinogenesis. 1993 May;14(5):969–973. [PubMed]
  • Hou SM, Lambert B, Hemminki K. Relationship between hprt mutant frequency, aromatic DNA adducts and genotypes for GSTM1 and NAT2 in bus maintenance workers. Carcinogenesis. 1995 Aug;16(8):1913–1917. [PubMed]
  • Langlois RG, Bigbee WL, Kyoizumi S, Nakamura N, Bean MA, Akiyama M, Jensen RH. Evidence for increased somatic cell mutations at the glycophorin A locus in atomic bomb survivors. Science. 1987 Apr 24;236(4800):445–448. [PubMed]
  • Langlois RG, Nisbet BA, Bigbee WL, Ridinger DN, Jensen RH. An improved flow cytometric assay for somatic mutations at the glycophorin A locus in humans. Cytometry. 1990;11(4):513–521. [PubMed]
  • Grant SG, Bigbee WL. In vivo somatic mutation and segregation at the human glycophorin A (GPA) locus: phenotypic variation encompassing both gene-specific and chromosomal mechanisms. Mutat Res. 1993 Jul;288(1):163–172. [PubMed]
  • Bigbee WL, Grant SG, Langlois RG, Jensen RH, Anttila A, Pfäffli P, Pekari K, Norppa H. Glycophorin A somatic cell mutation frequencies in Finnish reinforced plastics workers exposed to styrene. Cancer Epidemiol Biomarkers Prev. 1996 Oct;5(10):801–810. [PubMed]
  • Kreja L, Selig C, Plappert U, Nothdurft W. Radiation-induced DNA damage in canine hemopoietic cells and stromal cells as measured by the comet assay. Environ Mol Mutagen. 1996;27(1):39–45. [PubMed]
  • Bos JL, Verlaan-de Vries M, Jansen AM, Veeneman GH, van Boom JH, van der Eb AJ. Three different mutations in codon 61 of the human N-ras gene detected by synthetic oligonucleotide hybridization. Nucleic Acids Res. 1984 Dec 11;12(23):9155–9163. [PMC free article] [PubMed]
  • Balmain A, Brown K. Oncogene activation in chemical carcinogenesis. Adv Cancer Res. 1988;51:147–182. [PubMed]
  • Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. [PubMed]
  • Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993 Oct 28;329(18):1318–1327. [PubMed]
  • Puisieux A, Lim S, Groopman J, Ozturk M. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res. 1991 Nov 15;51(22):6185–6189. [PubMed]
  • Biggs PJ, Warren W, Venitt S, Stratton MR. Does a genotoxic carcinogen contribute to human breast cancer? The value of mutational spectra in unravelling the aetiology of cancer. Mutagenesis. 1993 Jul;8(4):275–283. [PubMed]
  • Aguilar F, Hussain SP, Cerutti P. Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8586–8590. [PubMed]
  • Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science. 1994 May 27;264(5163):1317–1319. [PubMed]
  • Amstad P, Hussain SP, Cerutti P. Ultraviolet B light-induced mutagenesis of p53 hotspot codons 248 and 249 in human skin fibroblasts. Mol Carcinog. 1994 Aug;10(4):181–188. [PubMed]
  • Esteve A, Sørlie T, Martel-Planche G, Hollstein M, Kusters I, Lewalter J, Vineis P, Stephan-Odenthal M, Montesano R. Screening for p53 gene mutations in archived tumors of workers occupationally exposed to carcinogens: examples from analysis of bladder tumors. J Occup Environ Med. 1995 Jan;37(1):59–68. [PubMed]
  • Husgafvel-Pursiainen K, Ridanpä M, Anttila S, Vainio H. p53 and ras gene mutations in lung cancer: implications for smoking and occupational exposures. J Occup Environ Med. 1995 Jan;37(1):69–76. [PubMed]
  • Takeshima Y, Seyama T, Bennett WP, Akiyama M, Tokuoka S, Inai K, Mabuchi K, Land CE, Harris CC. p53 mutations in lung cancers from non-smoking atomic-bomb survivors. Lancet. 1993 Dec 18;342(8886-8887):1520–1521. [PubMed]
  • Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, Couch MJ, Forastiere AA, Sidransky D. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med. 1995 Mar 16;332(11):712–717. [PubMed]
  • Ryberg D, Hewer A, Phillips DH, Haugen A. Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res. 1994 Nov 15;54(22):5801–5803. [PubMed]
  • Ryberg D, Kure E, Lystad S, Skaug V, Stangeland L, Mercy I, Børresen AL, Haugen A. p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer. Cancer Res. 1994 Mar 15;54(6):1551–1555. [PubMed]
  • Kawajiri K, Eguchi H, Nakachi K, Sekiya T, Yamamoto M. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res. 1996 Jan 1;56(1):72–76. [PubMed]
  • Myers RM, Larin Z, Maniatis T. Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA:DNA duplexes. Science. 1985 Dec 13;230(4731):1242–1246. [PubMed]
  • Smooker PM, Cotton RG. The use of chemical reagents in the detection of DNA mutations. Mutat Res. 1993 Jul;288(1):65–77. [PubMed]
  • Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci U S A. 1989 Apr;86(8):2766–2770. [PubMed]
  • Sekiya T. Detection of mutant sequences by single-strand conformation polymorphism analysis. Mutat Res. 1993 Jul;288(1):79–83. [PubMed]
  • Fan E, Levin DB, Glickman BW, Logan DM. Limitations in the use of SSCP analysis. Mutat Res. 1993 Jul;288(1):85–92. [PubMed]
  • Fischer SG, Lerman LS. DNA fragments differing by single base-pair substitutions are separated in denaturing gradient gels: correspondence with melting theory. Proc Natl Acad Sci U S A. 1983 Mar;80(6):1579–1583. [PubMed]
  • Cariello NF, Skopek TR. Mutational analysis using denaturing gradient gel electrophoresis and PCR. Mutat Res. 1993 Jul;288(1):103–112. [PubMed]
  • Hovig E, Smith-Sørensen B, Brøgger A, Børresen AL. Constant denaturant gel electrophoresis, a modification of denaturing gradient gel electrophoresis, in mutation detection. Mutat Res. 1991 Jan;262(1):63–71. [PubMed]
  • Khrapko K, Hanekamp JS, Thilly WG, Belenkii A, Foret F, Karger BL. Constant denaturant capillary electrophoresis (CDCE): a high resolution approach to mutational analysis. Nucleic Acids Res. 1994 Feb 11;22(3):364–369. [PMC free article] [PubMed]
  • Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989 Sep 1;49(17):4682–4689. [PubMed]
  • Pourzand C, Cerutti P. Genotypic mutation analysis by RFLP/PCR. Mutat Res. 1993 Jul;288(1):113–121. [PubMed]
  • Cerutti P, Hussain P, Pourzand C, Aguilar F. Mutagenesis of the H-ras protooncogene and the p53 tumor suppressor gene. Cancer Res. 1994 Apr 1;54(7 Suppl):1934s–1938s. [PubMed]
  • Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463–5467. [PubMed]
  • Pease AC, Solas D, Sullivan EJ, Cronin MT, Holmes CP, Fodor SP. Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc Natl Acad Sci U S A. 1994 May 24;91(11):5022–5026. [PubMed]
  • Hultman T, Ståhl S, Hornes E, Uhlén M. Direct solid phase sequencing of genomic and plasmid DNA using magnetic beads as solid support. Nucleic Acids Res. 1989 Jul 11;17(13):4937–4946. [PMC free article] [PubMed]
  • Syvänen AC, Söderlund H, Laaksonen E, Bengtström M, Turunen M, Palotie A. N-ras gene mutations in acute myeloid leukemia: accurate detection by solid-phase minisequencing. Int J Cancer. 1992 Mar 12;50(5):713–718. [PubMed]
  • Funa K, Steinholtz L, Nou E, Bergh J. Increased expression of N-myc in human small cell lung cancer biopsies predicts lack of response to chemotherapy and poor prognosis. Am J Clin Pathol. 1987 Aug;88(2):216–220. [PubMed]
  • Koutselini H, Kappatou G, Yiagnisis M, Field JK, Spandidos DA. Immunocytochemical study of RAS oncoprotein in cytologic specimens of primary lung tumours. Anticancer Res. 1990 May-Jun;10(3):597–603. [PubMed]
  • Gallick GE, Kurzrock R, Kloetzer WS, Arlinghaus RB, Gutterman JU. Expression of p21ras in fresh primary and metastatic human colorectal tumors. Proc Natl Acad Sci U S A. 1985 Mar;82(6):1795–1799. [PubMed]
  • Kurzrock R, Gallick GE, Gutterman JU. Differential expression of p21ras gene products among histological subtypes of fresh primary human lung tumors. Cancer Res. 1986 Mar;46(3):1530–1534. [PubMed]
  • Ruckle HC, Klee GG, Oesterling JE. Prostate-specific antigen: critical issues for the practicing physician. Mayo Clin Proc. 1994 Jan;69(1):59–68. [PubMed]
  • Ruckle HC, Klee GG, Oesterling JE. Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy. Mayo Clin Proc. 1994 Jan;69(1):69–79. [PubMed]
  • Brandt-Rauf PW. Biomarkers of gene expression: growth factors and oncoproteins. Environ Health Perspect. 1997 Jun;105 (Suppl 4):807–816. [PMC free article] [PubMed]
  • Ashby J, Anwar W, Au WW, Massoud A, Gentile JM. Genetic toxicology in developing countries: comments and recommendations. Environ Health Perspect. 1993 Oct;101 (Suppl 3):335–338. [PMC free article] [PubMed]
  • Anwar WA. Cytogenetic monitoring of human populations at risk in Egypt: role of cytogenetic data in cancer risk assessment. Environ Health Perspect. 1991 Dec;96:91–95. [PMC free article] [PubMed]
  • Burchell B, Coughtrie MW. Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation. Environ Health Perspect. 1997 Jun;105 (Suppl 4):739–747. [PMC free article] [PubMed]
  • Goldstein BD, Amoruso MA, Witz G. Erythrocyte glucose-6-phosphate dehydrogenase deficiency does not pose an increased risk for black Americans exposed to oxidant gases in the workplace or general environment. Toxicol Ind Health. 1985 Sep;1(1):75–80. [PubMed]
  • Ramel C. Mini- and microsatellites. Environ Health Perspect. 1997 Jun;105 (Suppl 4):781–789. [PMC free article] [PubMed]
  • Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol. 1990;39(6):533–537. [PubMed]
  • Daly AK, Cholerton S, Gregory W, Idle JR. Metabolic polymorphisms. Pharmacol Ther. 1993 Feb-Mar;57(2-3):129–160. [PubMed]
  • Horn EP, Tucker MA, Lambert G, Silverman D, Zametkin D, Sinha R, Hartge T, Landi MT, Caporaso NE. A study of gender-based cytochrome P4501A2 variability: a possible mechanism for the male excess of bladder cancer. Cancer Epidemiol Biomarkers Prev. 1995 Jul-Aug;4(5):529–533. [PubMed]
  • Pelkonen O, Raunio H. Metabolic activation of toxins: tissue-specific expression and metabolism in target organs. Environ Health Perspect. 1997 Jun;105 (Suppl 4):767–774. [PMC free article] [PubMed]
  • Vanden Heuvel JP, Clark GC, Thompson CL, McCoy Z, Miller CR, Lucier GW, Bell DA. CYP1A1 mRNA levels as a human exposure biomarker: use of quantitative polymerase chain reaction to measure CYP1A1 expression in human peripheral blood lymphocytes. Carcinogenesis. 1993 Oct;14(10):2003–2006. [PubMed]
  • Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 1988 Feb 4;331(6155):442–446. [PubMed]
  • Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem. 1990 Oct 5;265(28):17209–17214. [PubMed]
  • Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry. 1990 Feb 6;29(5):1322–1329. [PubMed]
  • Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem. 1991 Oct;110(4):559–565. [PubMed]
  • Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, Laughlin R, Nemoto T, Michalek AM, Harrington A, et al. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res. 1995 Aug 15;55(16):3483–3485. [PubMed]
  • Oyama T, Mitsudomi T, Kawamoto T, Ogami A, Osaki T, Kodama Y, Yasumoto K. Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP1A1 genotypes in Japanese. Int Arch Occup Environ Health. 1995;67(4):253–256. [PubMed]
  • Hayashi S, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem. 1991 Sep;110(3):407–411. [PubMed]
  • Zimmerman LJ, Fuscoe JC. Direct DNA sequencing of PCR products. Environ Mol Mutagen. 1991;18(4):274–276. [PubMed]
  • Birdsong WH, Lash AA, Thayer S, Kumekawa E, Becker CE. The validity of study group assignments based on occupational histories obtained from questionnaires. J Occup Med. 1992 Sep;34(9):940–945. [PubMed]
  • Hemminki K, Lindbohm ML, Kyyrönen P. Validity aspects of exposure and outcome data in reproductive studies. J Occup Environ Med. 1995 Aug;37(8):903–907. [PubMed]
  • London SJ, Daly AK, Thomas DC, Caporaso NE, Idle JR. Methodological issues in the interpretation of studies of the CYP2D6 genotype in relation to lung cancer risk. Pharmacogenetics. 1994 Apr;4(2):107–108. [PubMed]
  • Liu YH, Bai J, Zhu Y, Liang X, Siemieniak D, Venta PJ, Lubman DM. Rapid screening of genetic polymorphisms using buccal cell DNA with detection by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom. 1995;9(9):735–743. [PubMed]
  • Hirvonen A. Combinations of susceptible genotypes and individual responses to toxicants. Environ Health Perspect. 1997 Jun;105 (Suppl 4):755–758. [PMC free article] [PubMed]
  • Landi MT, Bertazzi PA, Shields PG, Clark G, Lucier GW, Garte SJ, Cosma G, Caporaso NE. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics. 1994 Oct;4(5):242–246. [PubMed]
  • Broly F, Marez D, Sabbagh N, Legrand M, Millecamps S, Lo Guidice JM, Boone P, Meyer UA. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics. 1995 Dec;5(6):373–384. [PubMed]
  • Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst. 1993 Jul 21;85(14):1159–1164. [PubMed]
  • Seidegård J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7293–7297. [PubMed]
  • Steen VM, Andreassen OA, Daly AK, Tefre T, Børresen AL, Idle JR, Gulbrandsen AK. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics. 1995 Aug;5(4):215–223. [PubMed]
  • Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11825–11829. [PubMed]
  • Vanden Heuvel JP, Clark GC, Kohn MC, Tritscher AM, Greenlee WF, Lucier GW, Bell DA. Dioxin-responsive genes: examination of dose-response relationships using quantitative reverse transcriptase-polymerase chain reaction. Cancer Res. 1994 Jan 1;54(1):62–68. [PubMed]
  • Raeymaekers L. A commentary on the practical applications of competitive PCR. Genome Res. 1995 Aug;5(1):91–94. [PubMed]
  • Kwok S, Higuchi R. Avoiding false positives with PCR. Nature. 1989 May 18;339(6221):237–238. [PubMed]
  • Varanasi U, Reichert WL, Stein JE. 32P-postlabeling analysis of DNA adducts in liver of wild English sole (Parophrys vetulus) and winter flounder (Pseudopleuronectes americanus). Cancer Res. 1989 Mar 1;49(5):1171–1177. [PubMed]
  • Stein JE, Reichert WL, Nishimoto M, Varanasi U. Overview of studies on liver carcinogenesis in English sole from Puget Sound; evidence for a xenobiotic chemical etiology. II: Biochemical studies. Sci Total Environ. 1990 May 1;94(1-2):51–69. [PubMed]
  • Adkisson PL, Niles GA, Walker JK, Bird LS, Scott HB. Controlling Cotton's Insect Pests: A New System. Science. 1982 Apr 2;216(4541):19–22. [PubMed]
  • Kurelec B. The multixenobiotic resistance mechanism in aquatic organisms. Crit Rev Toxicol. 1992;22(1):23–43. [PubMed]
  • Kurelec B. A new type of hazardous chemical: the chemosensitizers of multixenobiotic resistance. Environ Health Perspect. 1997 Jun;105 (Suppl 4):855–860. [PMC free article] [PubMed]
  • Minier C, Akcha F, Galgani F. P-glycoprotein expression in Crassostrea gigas and Mytilus edulis in polluted seawater. Comp Biochem Physiol B. 1993 Dec;106(4):1029–1036. [PubMed]
  • Waldmann P, Pivcevic B, Müller WE, Zahn RK, Kurelec B. Increased genotoxicity of acetylaminofluorene by modulators of multixenobiotic resistance mechanism: studies with the fresh water clam Corbicula fluminea. Mutat Res. 1995 Apr;342(3-4):113–123. [PubMed]
  • Kurelec B, Krca S, Pivcevic B, Ugarković D, Bachmann M, Imsiecke G, Müller WE. Expression of P-glycoprotein gene in marine sponges. Identification and characterization of the 125 kDa drug-binding glycoprotein. Carcinogenesis. 1992 Jan;13(1):69–76. [PubMed]
  • Holló Z, Homolya L, Davis CW, Sarkadi B. Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim Biophys Acta. 1994 May 11;1191(2):384–388. [PubMed]
  • Sarkadi B, Müller M, Homolya L, Holló Z, Seprödi J, Germann UA, Gottesman MM, Price EM, Boucher RC. Interaction of bioactive hydrophobic peptides with the human multidrug transporter. FASEB J. 1994 Jul;8(10):766–770. [PubMed]
  • Nebert DW, Nelson DR, Feyereisen R. Evolution of the cytochrome P450 genes. Xenobiotica. 1989 Oct;19(10):1149–1160. [PubMed]
  • Brattsten LB. Ecological significance of mixed-function oxidations. Drug Metab Rev. 1979;10(1):35–58. [PubMed]
  • Gregus Z, Watkins JB, Thompson TN, Harvey MJ, Rozman K, Klaassen CD. Hepatic phase I and phase II biotransformations in quail and trout: comparison to other species commonly used in toxicity testing. Toxicol Appl Pharmacol. 1983 Mar 15;67(3):430–441. [PubMed]
  • Anderson SL, Wild GC. Linking genotoxic responses and reproductive success in ecotoxicology. Environ Health Perspect. 1994 Dec;102 (Suppl 12):9–12. [PMC free article] [PubMed]
  • Schindler DW, Mills KH, Malley DF, Findlay DL, Shearer JA, Davies IJ, Turner MA, Linsey GA, Cruikshank DR. Long-term ecosystem stress: the effects of years of experimental acidification on a small lake. Science. 1985 Jun 21;228(4706):1395–1401. [PubMed]
  • Burger J. A risk assessment for lead in birds. J Toxicol Environ Health. 1995 Aug;45(4):369–396. [PubMed]
  • Burger J. Behavioral effects of early postnatal lead exposure in herring gull (Larus argentatus) chicks. Pharmacol Biochem Behav. 1990 Jan;35(1):7–13. [PubMed]
  • Burger J, Gochfeld M. Behavioral impairments of lead-injected young herring gulls in nature. Fundam Appl Toxicol. 1994 Nov;23(4):553–561. [PubMed]
  • Burger J, Gochfeld M. Lead and behavioral development in young herring gulls: effects of timing of exposure on individual recognition. Fundam Appl Toxicol. 1993 Aug;21(2):187–195. [PubMed]
  • Poland A, Clover E, Kende AS, DeCamp M, Giandomenico CM. 3,4,3',4'-Tetrachloro azoxybenzene and azobenzene: potent inducers of aryl hydrocarbon hydroxylase. Science. 1976 Nov 5;194(4265):627–630. [PubMed]
  • Poland A, Knutson JC. 2,3,7,8-tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. Annu Rev Pharmacol Toxicol. 1982;22:517–554. [PubMed]
  • Brunström B, Lund J. Differences between chick and turkey embryos in sensitivity to 3,3',4,4'-tetrachloro-biphenyl and in concentration/affinity of the hepatic receptor for 2,3,7,8-tetrachlorodibenzo-p-dioxin. Comp Biochem Physiol C. 1988;91(2):507–512. [PubMed]
  • Brunström B. Sensitivity of embryos from duck, goose, herring gull, and various chicken breeds to 3,3',4,4'-tetrachlorobiphenyl. Poult Sci. 1988 Jan;67(1):52–57. [PubMed]
  • Ashford NA. Policy considerations for human monitoring in the workplace. J Occup Med. 1986 Aug;28(8):563–568. [PubMed]
  • Atherley G, Johnston N, Tennassee M. Biomedical surveillance: rights conflict with rights. J Occup Med. 1986 Oct;28(10):958–965. [PubMed]
  • Lappé M. Ethical issues in testing for differential sensitivity to occupational hazards. J Occup Med. 1983 Nov;25(11):797–808. [PubMed]
  • Samuels SW. Medical surveillance: biological, social, and ethical parameters. J Occup Med. 1986 Aug;28(8):572–577. [PubMed]
  • Omenn GS. Predictive identification of hypersusceptible individuals. J Occup Med. 1982 May;24(5):369–374. [PubMed]
  • Perera FP. Molecular cancer epidemiology: a new tool in cancer prevention. J Natl Cancer Inst. 1987 May;78(5):887–898. [PubMed]
  • Schulte PA, Ringen K. Notification of workers at high risk: an emerging public health problem. Am J Public Health. 1984 May;74(5):485–491. [PubMed]
  • Schulte PA, Ringen K, Altekruse EB, Gullen WH, Davidson K, Anderson SS, Patton MG. Notification of a cohort of workers at risk of bladder cancer. J Occup Med. 1985 Jan;27(1):19–28. [PubMed]
  • Grandjean P, Sorsa M. Ethical aspects of genetic predisposition to environmentally-related disease. Sci Total Environ. 1996 May 17;184(1-2):37–43. [PubMed]
  • Hulka BS. ASPO Distinguished Achievement Award Lecture. Epidemiological studies using biological markers: issues for epidemiologists. Cancer Epidemiol Biomarkers Prev. 1991 Nov-Dec;1(1):13–19. [PubMed]
  • McMichael AJ. Invited commentary--"molecular epidemiology": new pathway or new travelling companion? Am J Epidemiol. 1994 Jul 1;140(1):1–11. [PubMed]
  • Pearce N, de Sanjose S, Boffetta P, Kogevinas M, Saracci R, Savitz D. Limitations of biomarkers of exposure in cancer epidemiology. Epidemiology. 1995 Mar;6(2):190–194. [PubMed]
  • Rothman N, Stewart WF, Caporaso NE, Hayes RB. Misclassification of genetic susceptibility biomarkers: implications for case-control studies and cross-population comparisons. Cancer Epidemiol Biomarkers Prev. 1993 Jul-Aug;2(4):299–303. [PubMed]
  • Van Damme K, Casteleyn L, Heseltine E, Huici A, Sorsa M, van Larebeke N, Vineis P. Individual susceptibility and prevention of occupational diseases: scientific and ethical issues. J Occup Environ Med. 1995 Jan;37(1):91–99. [PubMed]
  • Vineis P. Uses of biochemical and biological markers in occupational epidemiology. Rev Epidemiol Sante Publique. 1992;40 (Suppl 1):S63–S69. [PubMed]
  • Vineis P. Use of biomarkers in epidemiology. The example of metabolic susceptibility to cancer. Toxicol Lett. 1995 May;77(1-3):163–168. [PubMed]
  • Greenberg MR, Martell J. Ethical dilemmas and solutions for risk assessment scientists. J Expo Anal Environ Epidemiol. 1992 Oct-Dec;2(4):381–389. [PubMed]
  • Soskolne CL. Epidemiology: questions of science, ethics, morality, and law. Am J Epidemiol. 1989 Jan;129(1):1–18. [PubMed]
  • Summers Craig, Soskolne Colin L, Gotlieb Calvin, Fawcett Eric, McClusky Peter. Do scientific and scholarly codes of ethics take social issues into account? Account Res. 1995;4(1):57–68. [PubMed]
  • Sinkule JA, Stewart CF, Crom WR, Melton ET, Dahl GV, Evans WE. Teniposide (VM26) disposition in children with leukemia. Cancer Res. 1984 Mar;44(3):1235–1237. [PubMed]
  • Beach LR, Palmiter RD. Amplification of the metallothionein-I gene in cadmium-resistant mouse cells. Proc Natl Acad Sci U S A. 1981 Apr;78(4):2110–2114. [PubMed]
  • Marx J. Oncogenes evoke new cancer therapies. Science. 1990 Sep 21;249(4975):1376–1378. [PubMed]
  • Peltomäki P. DNA mismatch repair gene mutations in human cancer. Environ Health Perspect. 1997 Jun;105 (Suppl 4):775–780. [PMC free article] [PubMed]
  • Lewontin RC, Hartl DL. Population genetics in forensic DNA typing. Science. 1991 Dec 20;254(5039):1745–1750. [PubMed]
  • Stokinger HE. Letter: Carcinogen standard. A letter to the Assistant Secretary, Occupational Safety and Health--and a response. J Occup Med. 1974 Feb;16(2):119–120. [PubMed]
  • Vainio H, Husgafvel-Pursiainen K. Elimination of environmental factors or elimination of individuals: biomarkers and prevention. J Occup Environ Med. 1995 Jan;37(1):12–13. [PubMed]
  • Gochfeld M. Factors influencing susceptibility to metals. Environ Health Perspect. 1997 Jun;105 (Suppl 4):817–822. [PMC free article] [PubMed]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Science